Show simple item record

dc.contributor.authorRobertson, John F R
dc.contributor.authorHowell, Anthony
dc.contributor.authorBuzdar, Aman
dc.contributor.authorVon Euler, M
dc.contributor.authorLee, D
dc.date.accessioned2009-12-14T13:24:41Z
dc.date.available2009-12-14T13:24:41Z
dc.date.issued1999-11
dc.identifier.citationStatic disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. 1999, 58 (2):157-62 Breast Cancer Res. Treat.en
dc.identifier.issn0167-6806
dc.identifier.pmid10674881
dc.identifier.doi10.1023/A:1006391902868
dc.identifier.urihttp://hdl.handle.net/10541/87875
dc.description.abstractBACKGROUND: This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole. PATIENTS AND METHODS: All patients were part of two prospective, randomised, multicentre studies in postmenopausal women with advanced disease in which megestrol acetate was compared with anastrozole 1 mg. Survival from initiation of treatment was analysed by the response type, i.e., complete response (CR)/partial response (PR), static disease (SD) (> or = 24 weeks), or progressive disease (PD), achieved on therapy. RESULTS: Median survival with anastrozole 1 mg was similar between patients who obtained CR/PR and SD (> or = 24 weeks). Similarly, no difference in survival was observed in patients treated with megestrol acetate who achieved CR/PR and SD. With both treatments patients with CR/PR and SD had improved survival over those patients with PD within 24 weeks. There was no difference between treatment arms for patients showing PD within 24 weeks. CONCLUSIONS: These data confirm that durable SD (> or = 24 weeks) is a clinically useful remission criterion in postmenopausal women with advanced breast cancer with predictive value for overall survival. It also confirms the value of this endpoint with anastrozole, a new generation aromatase inhibitor.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshAromatase Inhibitors
dc.subject.meshBreast Neoplasms
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDouble-Blind Method
dc.subject.meshEnzyme Inhibitors
dc.subject.meshEurope
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMegestrol Acetate
dc.subject.meshNitriles
dc.subject.meshPostmenopause
dc.subject.meshProspective Studies
dc.subject.meshSurvival Analysis
dc.subject.meshTriazoles
dc.subject.meshUnited States
dc.titleStatic disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, City Hospital, Nottingham, UK. John.Robertson@nottingham.ac.uken
dc.identifier.journalBreast Cancer Research and Treatmenten
html.description.abstractBACKGROUND: This paper reports on the clinical relevance of durable static disease (SD) (> or = 24 weeks) in breast cancer patients treated with the aromatase inhibitor anastrozole. PATIENTS AND METHODS: All patients were part of two prospective, randomised, multicentre studies in postmenopausal women with advanced disease in which megestrol acetate was compared with anastrozole 1 mg. Survival from initiation of treatment was analysed by the response type, i.e., complete response (CR)/partial response (PR), static disease (SD) (> or = 24 weeks), or progressive disease (PD), achieved on therapy. RESULTS: Median survival with anastrozole 1 mg was similar between patients who obtained CR/PR and SD (> or = 24 weeks). Similarly, no difference in survival was observed in patients treated with megestrol acetate who achieved CR/PR and SD. With both treatments patients with CR/PR and SD had improved survival over those patients with PD within 24 weeks. There was no difference between treatment arms for patients showing PD within 24 weeks. CONCLUSIONS: These data confirm that durable SD (> or = 24 weeks) is a clinically useful remission criterion in postmenopausal women with advanced breast cancer with predictive value for overall survival. It also confirms the value of this endpoint with anastrozole, a new generation aromatase inhibitor.


This item appears in the following Collection(s)

Show simple item record